Dutogliptin
drugOn this page
Also known as DutogliptinaDutogliptinePhx1149
Summary
Dutogliptin (CHEMBL4296719) is a phase-3 clinical-stage small molecule; indicated across 2 conditions including type 2 diabetes mellitus and st-elevation myocardial infarction.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Small molecule
- Indications: 2 conditions
- Clinical trials: 10
- Chemistry: 241.1 Da · C10H20BN3O3
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4296719 |
| Name | Dutogliptin |
| Type | Small molecule |
| Max phase | 3 |
| FDA approved | no |
| PubChem CID | 11253490 |
| Molecular formula | C10H20BN3O3 |
| Molecular weight | 241.1 |
| InChIKey | DVJAMEIQRSHVKC-BDAKNGLRSA-N |
SMILES: B([C@@H]1CCCN1C(=O)CN[C@@H]2CCNC2)(O)O
IUPAC name: [(2R)-1-[2-[[(3R)-pyrrolidin-3-yl]amino]acetyl]pyrrolidin-2-yl]boronic acid
Also known as: Dutogliptin, Dutogliptina, Dutogliptine, Phx1149, PHX1149, DUTOGLIPTIN
Parent form; salt/anhydrous children: CHEMBL4297203
Patent coverage: 493 distinct patent families (1,373 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.
Targets
Targets
Broader ChEMBL bioactivity targets: 4 (assay-derived). Sample: Dipeptidyl peptidase 4, Dipeptidyl peptidase 8, Prolyl endopeptidase FAP, Dipeptidyl peptidase 9.
Bioactivity
ChEMBL activities: 5 potent at pChembl ≥ 5 of 5 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):
| Target | pChembl | Type | Value | Unit | Activity ID |
|---|---|---|---|---|---|
| DPP4 | 7.64 | IC50 | 23 | nM | CHEMBL_ACT_15714350 |
| DPP4 | 7.6 | IC50 | 25 | nM | CHEMBL_ACT_24689241 |
| DPP9 | 6.18 | IC50 | 663 | nM | CHEMBL_ACT_15714344 |
| FAP | 5.12 | IC50 | 7520 | nM | CHEMBL_ACT_15714326 |
| DPP8 | 5.07 | IC50 | 8427 | nM | CHEMBL_ACT_15714339 |
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| type 2 diabetes mellitus | 3 | MONDO:0005148 | MONDO:0005148 |
| ST-elevation myocardial infarction | 3 | MONDO:0041656 | EFO:0008585 |
Clinical trials
Total trials: 10.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 8 |
| PHASE2 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00850239 | PHASE3 | TERMINATED | Safety and Efficacy Study of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin |
| NCT00865592 | PHASE3 | TERMINATED | Long-term Study to Evaluate the Safety of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus |
| NCT00947557 | PHASE3 | TERMINATED | Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Glimepiride With or Without Metformin |
| NCT00958269 | PHASE3 | TERMINATED | Study to Evaluate Safety and Efficacy of Dutogliptin in Type 2 Diabetes Mellitus Subjects With Moderate and Severe Renal Impairment |
| NCT00970424 | PHASE3 | TERMINATED | Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus (T2DM) on Background Therapy With Pioglitazone |
| NCT00998686 | PHASE3 | TERMINATED | Safety and Efficacy Study of Dutogliptin in Subjects With Type 2 Diabetes Mellitus on a Background Medication of Metformin |
| NCT01089790 | PHASE3 | TERMINATED | Safety and Efficacy of Dutogliptin in Patients With Type 2 Diabetes Mellitus Receiving Background Treatment With Glimepiride Alone or in Combination With Metformin or With Pioglitazone Alone |
| NCT05881382 | PHASE3 | UNKNOWN | Dutogliptin in Co-administration With Filgrastim in Early Recovery Post-myocardial Infarction |
| NCT00530881 | PHASE2 | COMPLETED | Randomized, Double-Blind, Placebo-Controlled, With PHX1149 in Patients With Type 2 Diabetes Mellitus |
| NCT01101945 | PHASE2 | TERMINATED | Long-term Extension Study to Evaluate the Safety of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).